CriticalDirect oral anticoagulants (factor Xa inhibitors)×Low-molecular-weight heparin (LMWH)
Updated · Methodology
Mechanism
Edoxaban directly and reversibly inhibits clotting factor Xa and so reduces thrombin generation (edoxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). Enoxaparin is a low molecular weight heparin. Through antithrombin III, it strongly inhibits factor Xa and, more weakly, thrombin (enoxaparin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Edoxaban is contraindicated with any other anticoagulant because of the increased risk of bleeding, and this contraindication names enoxaparin (EMA). The enoxaparin SmPC lists anticoagulants among the drugs affecting haemostasis whose concomitant use with enoxaparin is not recommended (AEMPS).
Symptoms
Edoxaban increases the risk of bleeding, which can be severe or even fatal and can occur at any site (edoxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). The most frequently reported adverse reactions with edoxaban are nosebleeds, blood in the urine and anaemia. Bleeding can present as weakness, pallor, dizziness, headache, unexplained swelling, shortness of breath or shock with no apparent cause (EMA). Like any anticoagulant, enoxaparin can cause bleeding anywhere in the body. Neuraxial haematomas with prolonged or permanent paralysis have been reported in patients on enoxaparin who had spinal or epidural anaesthesia or lumbar puncture. The risk is higher with concomitant drugs that affect haemostasis (enoxaparin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS).
Management
Edoxaban is contraindicated with low molecular weight heparins, enoxaparin included (edoxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). The US label does not recommend long-term use of edoxaban with other anticoagulants (edoxaban label, US Food and Drug Administration, FDA). The switching exception in this contraindication covers oral anticoagulants. Do not give a parenteral anticoagulant and edoxaban at the same time, even during a switch (EMA). For deep vein thrombosis and pulmonary embolism, start edoxaban after at least 5 days of a parenteral anticoagulant, not together with it (EMA). When switching from enoxaparin, stop it and start edoxaban at the time of the next scheduled injection (EMA). The enoxaparin SmPC likewise says to stop enoxaparin when switching to a direct oral anticoagulant. Start the new drug 0–2 hours before the next scheduled injection, following its own SmPC (enoxaparin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). When switching from edoxaban to enoxaparin, stop edoxaban and give the first injection at the time of the next scheduled edoxaban dose. The enoxaparin SmPC says the same (EMA, AEMPS). If oral medicines cannot be taken during or after surgery, consider a parenteral anticoagulant and then switch to edoxaban (EMA). If severe bleeding occurs, stop edoxaban. There is no specific antidote, and protamine sulfate is not expected to affect edoxaban activity (EMA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: SAVAYSA (edoxaban) tablets, prescribing information (2023)– FDA, SAVAYSA (edoxaban tosylate) prescribing information, Daiichi Sankyo, NDA 206316, revised 10/2023 (DailyMed)
- EMA: Ficha técnica: Edoxabán, Lixiana 60 mg (EU/1/15/993), sección 4.3 (2025)– EMA SmPC vía AEMPS CIMA, Lixiana 60 mg comprimidos recubiertos con película (Daiichi Sankyo Europe), nº registro 115993018 (EU/1/15/993), información de producto EMA actualizada 27/08/2025, consultada 30.10.2026, secciones 4.2, 4.3, 4.4, 4.5, 4.8, 4.9 y 5.1
- AEMPS: Ficha técnica: Enoxaparina sódica, Clexane 10.000 UI (100 mg)/1 ml (nº registro 62472), sección 4.5 (2022)– AEMPS, CIMA, nº registro 62472 (Clexane 10.000 UI (100 mg)/1 ml solución inyectable en jeringa precargada, Sanofi Aventis), revisión del texto 02/2022, ficha técnica en CIMA del 07/10/2022, secciones 4.2, 4.4, 4.5 y 5.1